<DOC>
	<DOC>NCT00655330</DOC>
	<brief_summary>This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.</brief_summary>
	<brief_title>Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy</brief_title>
	<detailed_description>a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy - Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day) - Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Type 2 Diabetes nephropathy Urinary albumin excretion 13g/24hours Serum creatinine &lt; 3mg/dl Type 1 diabetes mellitus Renal diseases other than type 2 Diabetes nephropathy Renal artery stenosis Severe heart diseases Tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>valsartan</keyword>
	<keyword>probucol</keyword>
	<keyword>Proteinuria</keyword>
</DOC>